Selected article for: "cc NC International license and control group"

Author: Ming Zhong; Aijun Sun; Ting Xiao; Ge Yao; Ling Sang; Xia Zheng; Jinyan Zhang; Xuejuan Jin; Lei Xu; Wenlong Yang; Peng Wang; Kai Hu; Dingyu Zhang; Junbo Ge
Title: A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of a-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)
  • Document date: 2020_4_21
  • ID: mvsnybbo_7
    Snippet: We used mixed randomization for unpredictability in allocation sequences [25] . The allocation sequences were placed in the sealed opaque envelopes. We randomly assigned critically ill patients with COVID-19 to the treatment group and control . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity......
    Document: We used mixed randomization for unpredictability in allocation sequences [25] . The allocation sequences were placed in the sealed opaque envelopes. We randomly assigned critically ill patients with COVID-19 to the treatment group and control . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • allocation sequence and treatment group: 1, 2, 3
    • cc NC ND International license and control treatment group: 1
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and treatment group: 1, 2
    • control treatment group and International license: 1
    • control treatment group and mixed randomization: 1
    • control treatment group and treatment group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • International license and treatment group: 1, 2
    • mixed randomization and treatment group: 1
    • opaque envelope and sealed opaque envelope: 1, 2, 3